ArticleClinical rheumatology2026
Anti-centromere antibody positivity: a spectrum of clinical diagnoses and immunological patterns in a large patient cohort.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAnti-centromere antibody (ACA) positivity is recognized in diverse autoimmune diseases beyond systemic sclerosis (SSc). This study aimed to comprehensively characterize the clinical spectrum and serological profiles of ACA-positive (anti-CENP-B-positive) patients in a large cohort.
methodsThis retrospective study analyzed 1736 ACA-positive patients presenting from January 2016 to December 2023. Patients were categorized into defined systemic rheumatic and autoimmune liver disease group (Defined disease group); undifferentiated connective tissue disease (UCTD); symptomatic seropositive patients without a classifiable disease (Unclassified group); and other defined systemic diseases. Clinical characteristics, antinuclear antibody (ANA) patterns, and concomitant autoantibodies were extracted and compared between the four groups and different disease groups.
resultsThe cohort was predominantly female (94.38%), with a median age of 55 years. Defined disease group constituted 54.72% (n = 950), with primary biliary cholangitis (PBC, 23.80%) and Sjögren's syndrome (SS, 22.53%) being the most prevalent, followed by systemic lupus erythematosus (SLE, 13.92%), while SSc was only 6.16%. Patients in the defined disease group exhibited the highest proportion of strong anti-CENP-B reactivity (81.68%) and multiple autoantibodies (70.74%). Common co-occurring autoantibodies included anti-Ro52, anti-mitochondrial antibody M2 subtype (AMA-M2), anti-Sjögren syndrome A (anti-SSA), and anti-nuclear Ribonucleoprotein/Smith (anti-nRNP/Sm). Strong anti-CENP-B reactivity predominated in PBC (90.18%), SS (87.74%), autoimmune hepatitis (AIH, 91.53%), SSc (89.66%), and overlap syndrome (87.34%), whereas weak or moderate reactivity was relatively more frequent in SLE and rheumatoid arthritis (RA). Distinct ANA patterns and coexisting autoantibody profiles were observed across disease subgroups. Exploratory analyses further suggested that strong anti-CENP-B reactivity was associated with enrichment of centromere ANA patterns (64.05%), AMA-M2 positivity (31.44%), and liver cirrhosis (11.76%).
conclusionAnti-CENP-B-positive individuals represent a clinically heterogenous population with PBC and SS as the predominant defined autoimmune diseases. Distinct ANA patterns, coexisting autoantibody profiles, and anti-CENP-B reactivity may provide complementary information for clinical phenotyping and diagnostic evaluation. Key Points •Primary biliary cholangitis and Sjögren's syndrome, not systemic sclerosis, are the most common definitive autoimmune diseases in the large anti-CENP-B-positive patient cohort. •Distinct ANA patterns, coexisting autoantibody profiles, and anti-CENP-B reactivity were observed across different autoimmune phenotypes, supporting their complementary role in clinical phenotyping and diagnostic evaluation.
Indexed as
Identifiers
42618734What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.